Mitral Valve Insufficiency Clinical Trial
— TRACEROfficial title:
Mitral TRans-Apical neoChordal Echo-guided Repair (TRACER) Trial
Verified date | January 2024 |
Source | Edwards Lifesciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to evaluate the safety and performance of the Harpoon Medical device. It is anticipated, that the Harpoon Medical device will provide advantages over current surgical interventions including: 1) a small minimally invasive incision, 2) no sternotomy, 3) no cardiopulmonary bypass, 4) no aortic manipulation, 5) a direct path to the valve plane, 6) performed on a beating heart, 7) real-time TOE-guided chordal length adjustment and 8) less complicated procedure that is teachable and adoptable.
Status | Completed |
Enrollment | 26 |
Est. completion date | September 6, 2022 |
Est. primary completion date | November 6, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years - Patient referred for mitral valve surgery - Presence of severe MR as read on an echocardiographic study performed within 60 days prior to procedure - Estimated post-ePTFE chordae tendineae implantation coaptation surface is adequate in the judgment of the operating surgeon and the patient eligibility committee - Degenerative mitral valve disease - Patient is able to sign informed consent and able to return for follow-up and is capable of participating in all testing associated with this clinical investigation - Women of child-bearing potential have a negative pregnancy test Exclusion Criteria: - Age < 18 years - Infective endocarditis - Anterior or bileaflet prolapse - Functional MR - History of Mediastinal Radiation - Inflammatory (rheumatic) valve disease - Requirement for concomitant cardiac surgery (e.g., coronary artery bypass grafting (CABG), aortic valve surgery, etc.) - Symptomatic coronary artery disease - Cardiogenic shock at the time of enrollment - ST segment elevation myocardial infarction requiring intervention within 30 days prior to enrollment - Evidence of cirrhosis or hepatic synthetic failure - Pregnancy at the time of enrollment (women of child bearing age should have negative pregnancy within 14 days of surgery) - Severe pulmonary hypertension (PA systolic pressure > 70 mmHg) - Previous cardiac surgery, or surgery on the left pleural space - Left ventricular, atrial or appendage thrombus - Severely calcified mitral leaflets - Recent stroke (< 6 months) with permanent impairment - EuroScore (for mitral valve repair) > 8% - Patients with contraindications to Transoesophageal echocardiography - Severe left or right ventricular dysfunction - NYHA Class IV - Renal insufficiency CKD stage 3b or worse (GFR < 45 ml/min/1.73 m2) - Patient is participating in another clinical study for which follow-up is currently ongoing. (Co-enrollment in an investigational device or interventional study) - Patient with non-cardiac co-morbidities and life expectancy < 1 year - Patient has a condition or conditions that, in the opinion of the Investigator, preclude participation, including willingness to comply with all follow-up procedures |
Country | Name | City | State |
---|---|---|---|
Italy | Ospedale San Raffaele Hospital | Milan | |
Italy | University Hospital Padova | Padova | |
United Kingdom | The Royal Brompton and Harefield NHS Foundation Trust | London | |
United Kingdom | University Hospital Southampton NHS Trust | Southampton |
Lead Sponsor | Collaborator |
---|---|
Edwards Lifesciences |
Italy, United Kingdom,
Gammie JS, Bartus K, Gackowski A, D'Ambra MN, Szymanski P, Bilewska A, Kusmierczyk M, Kapelak B, Rzucidlo-Resil J, Moat N, Duncan A, Yadev R, Livesey S, Diprose P, Gerosa G, D'Onofrio A, Pitterello D, Denti P, La Canna G, De Bonis M, Alfieri O, Hung J, Ko — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Subject's Procedural Success During the First 30 Days | Procedural success was defined as the patient leaving the operating room with a successful implant of one or more ePTFE cords on the mitral valve and reduced mitral regurgitation from severe to =moderate at the conclusion of the procedure and at 30 days post-procedure. | End of procedure through 30 days | |
Primary | Percentage of Subject's With Freedom From Serious Adverse Events (SAE) </= 30 Days | Subject's freedom from Serious Adverse Events during the ePTFE implantation procedure and at 30 days follow-up. Time to events were estimated by Kaplan-Meier method. | Procedure and 30 days | |
Primary | Subject's Serious Adverse Events (SAE) Through Discharge | Number of Participants experiencing a Serious Adverse Event (SAE) through time of Discharge. | Discharge, an average of 5 days post implant | |
Secondary | Subject's Severity of Mitral Regurgitation Over Time | Valvular regurgitation occurs when the valve in the heart does not close tightly allowing some of the blood that was pumped out of the heart to leak back into it. Valvular regurgitation is evaluated by echocardiography over time. It is assessed on a scale from 0 to 4, where 0 represents no regurgitation and 4 represents severe regurgitation. The numbers on the scale are reflected as follows: 0 = no leak, 1 = a trace leak, 2 = a mild leak, 3 = a moderate leak, and 4 = a severe leak.
Higher numbers on the scale show a worsening outcome. |
6 months, 12 months, 18 months, 24 months, 30 months, and 36 months | |
Secondary | Percentage of Subject's With Freedom From Serious Adverse Events (SAE) Post-implant > 30 Days | Subject's freedom from Serious Adverse Events at >30 days post-implant. Time to events were estimated by Kaplan-Meier method. | 6 months, 12 months, 18 months, 24 months, 30 months, and 36 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03962023 -
Prognostic Impact of Imaging Parameters in Patients With Primary Mitral Insufficiency by Prolapse (COHORTE-IM)
|
||
Withdrawn |
NCT02624960 -
Safety and Performance of the AccuCinch® System
|
N/A | |
Terminated |
NCT02428010 -
Twelve Transcatheter Mitral Valve Replacement (TMVR) Pilot Study
|
N/A | |
Active, not recruiting |
NCT01533883 -
Cardioband Adjustable Annuloplasty System for Minimally Invasive Mitral Valve Repair
|
N/A | |
Unknown status |
NCT01201070 -
Study of Administration Of Antithrombin in Patients With Low Plasmatic Levels of Antithrombin After Cardiac Surgery
|
Phase 4 | |
Terminated |
NCT00700947 -
Using Beta Blockers to Treat Mitral Regurgitation
|
Phase 1 | |
Completed |
NCT04351984 -
Transcatheter Mitral Valvuloplasty Pilot Study
|
||
Completed |
NCT04231331 -
Ertugliflozin for Functional Mitral Regurgitation
|
Phase 3 | |
Completed |
NCT05742789 -
Effect of Anesthetics on Troponin I and ะก-reactive Protein
|
Phase 1 | |
Recruiting |
NCT02803957 -
Randomized Trial of the Neochord DS1000 System Versus Open Surgical Repair
|
N/A | |
Recruiting |
NCT04153292 -
The ENCIRCLE Trial
|
N/A | |
Completed |
NCT02607527 -
Annular Reshaping of the Mitral Valve for Patients With Mitral Regurgitation Using the Millipede IRIS System
|
N/A | |
Active, not recruiting |
NCT03066050 -
Long Term Follow Up for CTSN Mitral Valve Repair Studies
|
||
Active, not recruiting |
NCT04443218 -
Edwards PASCAL Transcatheter Valve Repair System Registry
|
||
Enrolling by invitation |
NCT04067635 -
Primary Mitral Regurgitation Repair
|
||
Completed |
NCT01966146 -
Examination of Valve Insufficiency Before and After MitraClip or TAVI Procedure by 3D Echocardiography Compared to MRI
|
N/A | |
Recruiting |
NCT01368575 -
Surgical Treatment of Ischemic Mitral Regurgitation
|
Phase 4 | |
Completed |
NCT00001314 -
Investigation of Heart Function in Patients With Heart Valve Defects
|
N/A | |
Terminated |
NCT03285724 -
Safety and Performance Study of the Harpoon Mitral Valve Repair System
|
N/A | |
Withdrawn |
NCT04709042 -
Acquisition of Objective Data During Transapical Neochordae Implantation
|
N/A |